Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and everolimus and to see how well they work in treating patients with advanced solid tumors.
Key facts
- Study ID
- NCT00303732
- Run by
- Daniel George, MD
- People needed
- 37
- Starts
- 2004-12-01
- Expected to finish
- 2012-08-01
- Last updated by the study team
- 2016-03-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.